2011 AAPS

2011 AAPS Annual Meeting and Exposition

AAPS, currently celebrating its 25th anniversary, has themed the keynote and plenary sessions for the 2011 Annual Meeting and Exposition “The Next 25 Years.” Colin M. Minchom, Ph.D., Annual Meeting Program Committee chair-elect, reflected on the planning process for the sessions, “When AAPS was formed in 1986, none of the founders anticipated the changes that led to today’s shape of the pharmaceutical sciences, the shape of the industry, the regulatory climate, and societal pressures on the cost-benefit of therapies. What will happen in our industry in the next 25 years?”

A panel of visionary opinion leaders will provide their insights in each of these spheres at the general sessions of the 2011 Annual Meeting and Exposition.

As the keynote speaker on Sunday, October 23, Janet Woodcock, M.D., director of the Center for Drug Evaluation and Research at the Food and Drug Administration, will provide her views on regulation into the future.

On Monday, October 24, at the plenary session, John Lechleiter, Ph.D., president and chief executive officer, Eli Lilly and Company, will speak to the future shape of the global pharmaceutical industry; Francis S. Collins, M.D., Ph.D., director, U.S. National Institutes of Health, will speak on current research that may lead to new therapies in the future. Sir Michael Rawlins, M.D., chairman of the National Institute of Health & Clinical Excellence (NICE) of the United Kingdom, will speak on the cost benefits of therapies and the societal ability to pay for the therapies, “Value for Money in Healthcare: The Future.” NICE is an independent organization responsible for providing national guidance on promoting good health and preventing and treating ill health.